|August 26, 2013|
|09:53 EDT||AMGN||Amgen runs higher following Onyx acquisition, levels to watch|
Shares are at $113.70, up over 7.6%, following the company's acquisition of Onyx (ONXX). At current price, next resistance is at $114.95, the 52-week high and life high. Support is at $112.40.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
|December 6, 2013|
|08:31 EDT||AMGN||Amgen unit, International Myeloma Foundation announce partnership|
The International Myeloma Foundation and Onyx Pharmaceuticals, an Amgen subsidiary, announced the start of a multi-year collaboration in support of the IMF's Black Swan Research Initiative. The BSRI is led by a multinational consortium of leading myeloma experts who are studying and harnessing new technologies and treatments with the goal of developing a cure for myeloma.
|06:19 EDT||AMGN||Amgen price target lowered to $131 from $139 at Citigroup|
Citigroup lowered its price target for Amgen shares to $131 after dropping its estimates for the company's myeloma drug Kyprolis to below consensus. Citi believes the drug's inconvenience and cardiac toxicities are limiting its uptake and while drugs in late stage development offer far more appealing profiles. Citi, however, keeps a Buy rating on Amgen.
|December 3, 2013|
|09:37 EDT||AMGN||Active equity options trading on open|
Active equity options trading on open according to Track Data: CELG YHOO BX ARIA GS NXPI DG AMGN SLW MRK
|December 2, 2013|
|14:03 EDT||AMGN||Amgen pegfilgrastim granted orphan status for treatment of myelosuppression|
|November 27, 2013|
|13:05 EDT||AMGN||Amgen Neupogen granted orphan designation by FDA|
The drug received orphan designation for treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident. Reference Link
|November 26, 2013|
|16:14 EDT||AMGN||Amgen coverage resumed with an Overweight at Piper Jaffray|